XML 67 R48.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Fair Value of Financial Instruments - Schedule of Quantitative Information of Fair Value Measurements (Details) - Significant Unobservable Inputs (Level 3) $ in Thousands | Dec. 31, 2024 USD ($) | Dec. 31, 2023 USD ($)
--- | --- | ---
Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investments | $ 3,494,601 | $ 3,057,299
Equity and Warrant Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investments | 120,218 | 116,916
Debt Investments And Other Investment Receivables |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investments | 3,493,589 | 3,066,947
Market Comparable Companies | Equity Securities |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investments | 45,420 | 52,094
Market Comparable Companies | Warrants |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investments | 18,302 | 19,014
Market Comparable Companies | Pharmaceuticals | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investments | 947,065 | 971,775
Market Comparable Companies | Technology | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investments | 1,365,943 | 1,181,823
Market Comparable Companies | Sustainable and Renewable Technology | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investments | 21,102 | 1,678
Market Comparable Companies | Medical Devices | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investments | 59,645 |
Market Comparable Companies | Lower Middle Market | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investments | $ 636,258 | $ 322,162
Market Comparable Companies | Hypothetical Market Yield | Technology | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.1310 |
Market Comparable Companies | Premium/(Discount) | Technology | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input |  | 0.0047
Market Comparable Companies | Minimum | Hypothetical Market Yield | Pharmaceuticals | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.0842 | 0.1091
Market Comparable Companies | Minimum | Hypothetical Market Yield | Technology | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.1021 | 0.1130
Market Comparable Companies | Minimum | Hypothetical Market Yield | Sustainable and Renewable Technology | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.1241 | 0.1075
Market Comparable Companies | Minimum | Hypothetical Market Yield | Medical Devices | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.1179 |
Market Comparable Companies | Minimum | Hypothetical Market Yield | Lower Middle Market | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.1027 | 0.1254
Market Comparable Companies | Minimum | Premium/(Discount) | Pharmaceuticals | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | (0.0250) | (0.0100)
Market Comparable Companies | Minimum | Premium/(Discount) | Technology | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | (0.0075) | (0.0100)
Market Comparable Companies | Minimum | Premium/(Discount) | Sustainable and Renewable Technology | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.0025 | 0.0075
Market Comparable Companies | Minimum | Premium/(Discount) | Medical Devices | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.0000 |
Market Comparable Companies | Minimum | Premium/(Discount) | Lower Middle Market | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | (0.0025) | (0.0075)
Market Comparable Companies | Minimum | EBITDA Multiple | Equity Securities |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input |  | 12.3
Market Comparable Companies | Minimum | EBITDA Multiple | Warrants |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input |  | 12.3
Market Comparable Companies | Minimum | Revenue Multiple | Equity Securities |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.4 | 0.3
Market Comparable Companies | Minimum | Revenue Multiple | Warrants |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.8 | 0.9
Market Comparable Companies | Minimum | Tangible Book Value Multiple | Equity Securities |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 1.7 | 1.8
Market Comparable Companies | Minimum | Discount for Lack of Marketability | Equity Securities |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.1764 | 0.0711
Market Comparable Companies | Minimum | Discount for Lack of Marketability | Warrants |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.1472 | 0.0621
Market Comparable Companies | Maximum | Hypothetical Market Yield | Pharmaceuticals | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.1619 | 0.2143
Market Comparable Companies | Maximum | Hypothetical Market Yield | Technology | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.2058 | 0.2074
Market Comparable Companies | Maximum | Hypothetical Market Yield | Sustainable and Renewable Technology | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.1544 | 0.1075
Market Comparable Companies | Maximum | Hypothetical Market Yield | Medical Devices | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.1275 |
Market Comparable Companies | Maximum | Hypothetical Market Yield | Lower Middle Market | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.2100 | 0.2015
Market Comparable Companies | Maximum | Premium/(Discount) | Pharmaceuticals | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.0300 | 0.0350
Market Comparable Companies | Maximum | Premium/(Discount) | Technology | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.0450 | 0.0500
Market Comparable Companies | Maximum | Premium/(Discount) | Sustainable and Renewable Technology | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.0350 | 0.0075
Market Comparable Companies | Maximum | Premium/(Discount) | Medical Devices | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.0050 |
Market Comparable Companies | Maximum | Premium/(Discount) | Lower Middle Market | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.0500 | 0.0225
Market Comparable Companies | Maximum | EBITDA Multiple | Equity Securities |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input |  | 12.3
Market Comparable Companies | Maximum | EBITDA Multiple | Warrants |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input |  | 12.3
Market Comparable Companies | Maximum | Revenue Multiple | Equity Securities |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 16.8 | 20.1
Market Comparable Companies | Maximum | Revenue Multiple | Warrants |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 14.1 | 10.2
Market Comparable Companies | Maximum | Tangible Book Value Multiple | Equity Securities |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 1.7 | 1.8
Market Comparable Companies | Maximum | Discount for Lack of Marketability | Equity Securities |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.9280 | 0.9272
Market Comparable Companies | Maximum | Discount for Lack of Marketability | Warrants |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.3435 | 0.3312
Market Comparable Companies | Weighted Average | Hypothetical Market Yield | Pharmaceuticals | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.1203 | 0.1346
Market Comparable Companies | Weighted Average | Hypothetical Market Yield | Technology | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input |  | 0.1503
Market Comparable Companies | Weighted Average | Hypothetical Market Yield | Sustainable and Renewable Technology | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.1525 | 0.1075
Market Comparable Companies | Weighted Average | Hypothetical Market Yield | Medical Devices | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.1224 |
Market Comparable Companies | Weighted Average | Hypothetical Market Yield | Lower Middle Market | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.1412 | 0.1413
Market Comparable Companies | Weighted Average | Premium/(Discount) | Pharmaceuticals | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.0013 | 0.0004
Market Comparable Companies | Weighted Average | Premium/(Discount) | Technology | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.0020 |
Market Comparable Companies | Weighted Average | Premium/(Discount) | Sustainable and Renewable Technology | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.0045 | 0.0075
Market Comparable Companies | Weighted Average | Premium/(Discount) | Medical Devices | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.0026 |
Market Comparable Companies | Weighted Average | Premium/(Discount) | Lower Middle Market | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.0107 | 0.0056
Market Comparable Companies | Weighted Average | EBITDA Multiple | Equity Securities |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input |  | 12.3
Market Comparable Companies | Weighted Average | EBITDA Multiple | Warrants |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input |  | 12.3
Market Comparable Companies | Weighted Average | Revenue Multiple | Equity Securities |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 9.1 | 7.2
Market Comparable Companies | Weighted Average | Revenue Multiple | Warrants |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 4.5 | 4.2
Market Comparable Companies | Weighted Average | Tangible Book Value Multiple | Equity Securities |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 1.7 | 1.8
Market Comparable Companies | Weighted Average | Discount for Lack of Marketability | Equity Securities |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.3612 | 0.3157
Market Comparable Companies | Weighted Average | Discount for Lack of Marketability | Warrants |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.2676 | 0.2170
Liquidation | Accounts Payable and Accrued Liabilities |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investments | $ (1,012) |
Liquidation | Other Investment Receivables |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investments |  | $ 9,648
Liquidation | Pharmaceuticals | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investments | 55,344 | 8,455
Liquidation | Technology | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investments | $ 51,004 | $ 0
Liquidation | Minimum | Probability weighting of alternative outcomes | Accounts Payable and Accrued Liabilities |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.2000 |
Liquidation | Minimum | Probability weighting of alternative outcomes | Other Investment Receivables |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input |  | 0.1000
Liquidation | Minimum | Probability weighting of alternative outcomes | Pharmaceuticals | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.2000 | 0.1000
Liquidation | Minimum | Probability weighting of alternative outcomes | Technology | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.2200 | 1.0000
Liquidation | Maximum | Probability weighting of alternative outcomes | Accounts Payable and Accrued Liabilities |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.5000 |
Liquidation | Maximum | Probability weighting of alternative outcomes | Other Investment Receivables |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input |  | 0.5000
Liquidation | Maximum | Probability weighting of alternative outcomes | Pharmaceuticals | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.8000 | 0.5000
Liquidation | Maximum | Probability weighting of alternative outcomes | Technology | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.7800 | 1.0000
Liquidation | Weighted Average | Probability weighting of alternative outcomes | Accounts Payable and Accrued Liabilities |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.3844 |
Liquidation | Weighted Average | Probability weighting of alternative outcomes | Other Investment Receivables |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input |  | 0.4183
Liquidation | Weighted Average | Probability weighting of alternative outcomes | Pharmaceuticals | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.7553 | 0.4183
Liquidation | Weighted Average | Probability weighting of alternative outcomes | Technology | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.6634 | 1.0000
Convertible Note Analysis | Technology | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investments | $ 26,869 | $ 23,244
Convertible Note Analysis | Minimum | Probability weighting of alternative outcomes | Technology | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.0100 | 0.0100
Convertible Note Analysis | Maximum | Probability weighting of alternative outcomes | Technology | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.7000 | 0.5000
Convertible Note Analysis | Weighted Average | Probability weighting of alternative outcomes | Technology | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.5066 | 0.3932
Cost Approach | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investments | $ 242,833 | $ 431,512
Debt Investments Imminent Payoffs | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investments | 4,141 | 54,430
Debt Maturing Within One Year | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investments | 36,185 | 62,220
Market Adjusted OPM Backsolve | Equity Securities |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investments | 12,374 | 11,096
Market Adjusted OPM Backsolve | Warrants |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investments | $ 3,521 | $ 3,074
Market Adjusted OPM Backsolve | Minimum | Market Equity Adjustment | Equity Securities |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | (0.9657) | (0.8614)
Market Adjusted OPM Backsolve | Minimum | Market Equity Adjustment | Warrants |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | (0.5636) | (0.7067)
Market Adjusted OPM Backsolve | Maximum | Market Equity Adjustment | Equity Securities |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.2476 | 0.3269
Market Adjusted OPM Backsolve | Maximum | Market Equity Adjustment | Warrants |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.2476 | 0.3486
Market Adjusted OPM Backsolve | Weighted Average | Market Equity Adjustment | Equity Securities |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | (0.1757) | 0.0747
Market Adjusted OPM Backsolve | Weighted Average | Market Equity Adjustment | Warrants |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.0133 | 0.1317
Discounted Cash Flow | Equity Securities |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investments | $ 34,677 | $ 28,713
Discounted Cash Flow | Minimum | Discount Rate | Equity Securities |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.1217 | 0.1988
Discounted Cash Flow | Maximum | Discount Rate | Equity Securities |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.3334 | 0.3197
Discounted Cash Flow | Weighted Average | Discount Rate | Equity Securities |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investment company, investment owned, measurement input | 0.3021 | 0.3051
Other | Equity Securities |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investments | $ 5,924 | $ 2,925
Other | Warrants |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investments |  | $ 0
Debt Investments In Wholly-Owned Subsidiaries | Debt Investments |  |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] |  |
Investments | $ 48,212 |

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Value of input used to measure investment owned by investment company. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_InvestmentCompanyInvestmentOwnedFairValueMeasurementInput
Namespace Prefix: | us-gaap_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | instant

X
- Definition Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_InvestmentsFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=htgc_DebtInvestmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=htgc_EquityAndWarrantInvestmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=htgc_DebtInvestmentsAndOtherInvestmentReceivablesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ValuationTechniqueAxis=us-gaap_MarketApproachValuationTechniqueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_EquitySecuritiesByIndustryAxis=htgc_PharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_EquitySecuritiesByIndustryAxis=htgc_TechnologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_EquitySecuritiesByIndustryAxis=htgc_SustainableAndRenewableTechnologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_EquitySecuritiesByIndustryAxis=htgc_MedicalDevicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_EquitySecuritiesByIndustryAxis=htgc_LowerMiddleMarketMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=htgc_MeasurementInputHypotheticalMarketYieldMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=htgc_MeasurementInputPremiumDiscountNettingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputEbitdaMultipleMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRevenueMultipleMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=htgc_MeasurementInputTangibleBookValueMultipleMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_WeightedAverageMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ValuationTechniqueAxis=htgc_ValuationTechniqueLiquidationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=htgc_OtherInvestmentReceivablesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=htgc_MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ValuationTechniqueAxis=us-gaap_IncomeApproachValuationTechniqueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ValuationTechniqueAxis=us-gaap_CostApproachValuationTechniqueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ValuationTechniqueAxis=htgc_DebtInvestmentsImminentPayoffsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ValuationTechniqueAxis=htgc_DebtMaturingWithinOneYearMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=htgc_MeasurementInputMarketEquityAdjustmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ValuationTechniqueAxis=htgc_ValuationTechniqueOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ValuationTechniqueAxis=htgc_DebtInvestmentsInWhollyOwnedSubsidiariesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |